
Nephrology consultant, #FOAMed, photography lover, and a traveller
- Tweets913
- Following1.1K
- Followers1.1K
- Likes1.6K

ALT Visual abstract NC-033: EVOLVE trial. 3,883 adults on haemodialysis with secondary hyperparathyroidism, cinacalcet versus placebo, median 21 months. Primary composite of death and cardiovascular events HR 0.93 (95% CI 0.85 to 1.02), not significant. Fewer parathyroidectomies and less calciphylaxis.

ALT Visual abstract NC-032: calciphylaxis. Very painful violaceous net-like plaques that ulcerate, mostly in dialysis patients. Risk factors include female sex, obesity, diabetes, warfarin, high phosphate and calcium load. Stop warfarin, calcium and vitamin D, optimise dialysis, phosphate and PTH, provide wound and pain care; sodium thiosulfate is off-label.

ALT Visual abstract NC-031: secondary hyperparathyroidism. Not on dialysis: optimal PTH unknown, correct phosphate, calcium and vitamin D deficiency, calcitriol only if severe and progressive, no calcimimetics. On dialysis: PTH target about 2 to 9 times upper limit, calcimimetics or calcitriol, parathyroidectomy if refractory.

